An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
Phase 3 study finds inebilizumab effective for immunoglobulin G4–related disease
- Post author:
- Post published:November 14, 2024
- Post category:uncategorized